TL;DR
This case report details a successful treatment regimen for a rare and aggressive form of pulmonary epithelioid hemangioendothelioma (PE-EHE) using a combination of chemotherapy and immunotherapy. The study highlights the diagnostic challenges and proposes that a specific genetic mutation (MSH2) may play a role in the disease's development, potentially guiding future treatment strategies.
What Problem Does This Paper Address?
Primary pulmonary endovascular epithelioid hemangioendothelioma (PE-EHE) is an exceptionally rare and often aggressive malignancy. Diagnosing PE-EHE is challenging because its presentation can mimic other conditions like chronic pulmonary embolism or pulmonary artery sarcoma, leading to delayed treatment. Furthermore, there's a lack of established optimal treatment protocols for PE-EHE, with current therapeutic approaches largely based on limited case series. This paper addresses the need for better diagnostic strategies and effective treatment options for this difficult-to-manage disease.
Methods
The study employed a combination of advanced imaging techniques and histopathological analysis for diagnosis. Computed tomography pulmonary angiography (CTPA) and 18-fluorodeoxyglucose/fibroblast associated protein inhibitor-positron emission tomography/computed tomography (18F-FDG/FAPI-PET/CT) were used to visualize the endovascular lesions. A percutaneous transluminal pulmonary biopsy was performed for definitive diagnosis, followed by histopathological examination including hematoxylin and eosin (H.E.) staining and immunohistochemistry for markers like CD31, CD34, CAMTA1, and Ki-67 to assess cell proliferation. Genetic analysis, specifically whole-genome sequencing of peripheral blood, was conducted to identify potential mutations. The treatment involved a regimen of paclitaxel and carboplatin chemotherapy, followed by pembrolizumab immunotherapy.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Diagnostic Mimicry: PE-EHE can be easily mistaken for more common vascular conditions, underscoring the importance of high-resolution imaging and biopsy for accurate diagnosis.
- Genetic Clues: The identification of an MSH2 gene mutation (p.Y656) in the patient's peripheral blood is a significant finding. This mutation, involved in DNA repair, suggests a potential role in the pathogenesis of PE-EHE and opens avenues for targeted therapies.
- Combined Treatment Efficacy: The successful outcome achieved with a combination of chemotherapy (paclitaxel and carboplatin) and immunotherapy (pembrolizumab) provides a promising treatment paradigm for PE-EHE.
- Imaging as a Guide: The use of 18F-FDG/FAPI-PET/CT not only aided in diagnosis but also in monitoring treatment response, showing a reduction in lesion uptake after therapy.
Key Results
The patient, a 42-year-old male, presented with symptoms initially misdiagnosed as acute pulmonary embolism. After a thorough diagnostic workup including CTPA and 18F-FDG/FAPI-PET/CT, a percutaneous biopsy confirmed PE-EHE. Histopathology revealed low proliferative activity (Ki-67 of 5%) and positive staining for CD31, CD34, and CAMTA1. Genetic analysis identified an MSH2 mutation (p.Y656). The patient responded remarkably well to 5 cycles of paclitaxel and carboplatin chemotherapy, followed by pembrolizumab maintenance therapy. Post-treatment imaging showed significant inhibition of the lesions.
Limitations and Future Work
The primary limitation of this study is its nature as a single case report, which limits the generalizability of the findings. While the MSH2 mutation was identified, its precise role in PE-EHE pathogenesis and its impact on immunotherapy response require further investigation. Future work should focus on larger cohort studies to validate these findings, explore the prognostic significance of MSH2 mutations in PE-EHE, and investigate the efficacy of similar combination therapies in a broader patient population. Further research into the molecular mechanisms underlying PE-EHE, particularly the role of genetic mutations and their interaction with the tumor microenvironment, is also warranted.
Summary updated